Resources to get started right

Receive guidance on co-pay assistance and reimbursement matters.

Learn more

Questions about cutaquig?

Find helpful answers to common questions about cutaquig and PI.

Learn more

  1. Cutaquig Full Prescribing Information. Paramus, NJ: Octapharma; rev October 2021.
  2. Kobayashi RH, Gupta S, Melamed I, et al. Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies. Front Immunol. 2019;10(40):1-12.
  3. Kobayashi RH, Mandujano JF, Rehman SM, et al. Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm]). Immunotherapy. 2021;13(10):813 -824.